PuSH - Publikationsserver des Helmholtz Zentrums München

Mukama, T.* ; Fortner, R.T.* ; Katzke, V.* ; Hynes, L.C.* ; Petrera, A. ; Hauck, S.M. ; Johnson, T.* ; Schulze, M.* ; Schiborn, C.* ; Rostgaard-Hansen, A.L.* ; Tjønneland, A.* ; Overvad, K.* ; Pérez, M.J.S.* ; Crous-Bou, M.* ; Chirlaque, M.D.* ; Amiano, P.* ; Ardanaz, E.* ; Watts, E.L.* ; Travis, R.C.* ; Sacerdote, C.* ; Grioni, S.* ; Masala, G.* ; Signoriello, S.* ; Tumino, R.* ; Gram, I.T.* ; Sandanger, T.M.* ; Sartor, H.* ; Lundin, E.* ; Idahl, A.* ; Heath, A.K.* ; Dossus, L.* ; Weiderpass, E.* ; Kaaks, R.*

Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.

Br. J. Cancer (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. METHODS: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. RESULTS: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9-18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. CONCLUSION: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0-9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Trial
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Zeitschrift British Journal of Cancer BJC
Verlag Nature Publishing Group
Verlagsort Campus, 4 Crinan St, London, N1 9xw, England
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) CF Metabolomics & Proteomics (CF-MPC)
Förderungen RCUK | Medical Research Council (MRC)
Cancer Research UK (CRUK)